Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer

Medical Hypotheses

Volumn 67, Issue 6, 2006, Pages 1375-1380

  Rubenstein, Marvin ^a,b   Anderson, Kenning M ^a   Tsui, Paulus ^a   Guinan, Patrick ^a,c  

^a Hektoen Institute for Medical Research   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; ENHANCED GREEN FLUORESCENT PROTEIN; MESSENGER RNA; NANOPARTICLE; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR ALPHA;

APOPTOSIS; ARTICLE; BINDING SITE; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; HORMONE RESISTANCE; HUMAN; MEMBRANE; PRIORITY JOURNAL; PROSTATE CANCER; SYNTHESIS;

CELL LINE, TUMOR; DENDRIMERS; HUMANS; MALE; MODELS, BIOLOGICAL; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; SOLUBILITY; TREATMENT OUTCOME;

EID: 33748968813     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.05.055     Document Type: Article

References (17)

1. Felsenfeld G., and Miles H.T. Formulation of a three-stranded polynucleotide molecule. J Amer Chem Soc 79 (1957) 2023-2024
2. Guvakova M.A., Yakubov L., Vlodavsky I., Tonkinson J.L., and Stein C.A. Phosphorothioate oligonucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 270 (1995) 2620-2627
3. Rubenstein M., Mirochnik Y., Bremer E., George D., Frilich L., and Guinan P. Inhibitory effect of antisense oligonucleotides targeting epidermal growth factor receptor may not be related to changes in mRNA levels in human prostate cancer cells. Proc Am Assoc Cancer Res 43 (2002) 590a
4. Zamecnik P.C., and Stephenson M.L. Inhibition of Rous sarcoma virus replication and transformation by a specific deoxynucleotide. Proc Natl Acad Sci USA 75 (1979) 280-284
5. Rubenstein M., Tsui P., and Guinan P. A review of antisense oligonucleotides in the treatment of human disease. Drugs Future 29 (2004) 893-909
6. Rubenstein M., Mirochnik Y., Chou P., and Guinan P. Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol 62 (1996) 194-200
7. Yamanaka K., Miyake H., Zangemeister-wittke U., Jansen B., and Gleave M. Novel bispecific antisense oligonucleotides inhibiting both bcl-2 and bcl-xl expression induce apoptosis and enhance chemosensitivity in human androgen-independent prostate cancer cells. Proc Am Assoc Cancer Res (2004) 45 [Abstract 2930]
8. Rubenstein M., Tsui P., and Guinan P. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors. Med Hypotheses 65 (2005) 905-907
9. Eder IE, Haag P, Steiner H, Berger AP, Frauscher F, Seitz A, et al. In vivo delivery of an antisense oligonucleotide into prostate tumors with the help of microbubble-carriers and ultrasound. Presented at Fall Joint SBUR-ESUR Meeting, December 1-4, 2005, Miami Beach, FL. Poster #95.
10. Smith R.A.J., Porteous C.M., Coulter C.V., and Murphy M.P. Selective targeting of an antioxidant to mitochodria. Eur J Biochem 263 (1999) 709-716
11. Anderson K.M., Seed T.M., Alrefai W., Ou D., and Harris J.E. NTBN, A free radical spin trap induces programmed cell death in human pancreatic cancer (PANC-1) cells. Anticancer Res 18 (1998) 3213-3222
12. Pardridge WM. Transcellular drug delivery of antisense oligonucleotide-based therapeutics through the blood brain barrier in vivo. IBC Conf Commerc Oligonucleotide-Based Ther, Coronado, December 6-7, 1993.
13. Spitaly GL. Targeted delivery of antisense DNA for treatment of hepatitis B viral infection. IBC Conf Commerc Oligonucleotide-Based Ther, Coronado, December 6-7, 1993.
14. Lee B.-S., Fujita M., Ljubimova J.Y., and Holler E. Delivery of antisense oligonucleotides and transferrin receptor antibody in vitro and in vivo using a new multifunctional drug delivery system based on polymalic acid. Proc Am Assoc Cancer Res 45 (2004) 647a
15. Santhakumaran L., Thomas T., and Thomas T.J. Nanoparticle formation in an antisense oligonucleotide by polypropylinimine dendrimers: facilitation of cellular uptake and intracellular stability. Proc Am Assoc Cancer Res 45 (2004) 2938a
16. Levitt R., Gleave M.E., and Polack M. Bispecific antisense oligonucleotides targeting both IGFBP-2 and IGFBP-5 inhibits growth of U87 glioma cells. Proc Am Assoc Cancer Res (2004) 45 [Abstract 1427]
17. Signaevsky M., Beraldi E., Li D., Cox M., and Gleave M.E. IFGBP-2 and IGFBP-5 bispecific antisense oligonucleotides decrease cell survival via induction of apoptosis through alteration of IGF-1 signaling. Proc Am Assoc Cancer Res (2004) 45 [Abstract 5338]